Modafinil, sold under the brand name Provigil among others, is a central nervous system (CNS) stimulant medication used to treat sleepiness due to narcolepsy, shift work sleep disorder, and obstructive sleep apnea. It is sometimes prescribed off-label for treating Attention deficit hyperactivity disorder (ADHD) in children, having no benefit in ADHD for most adults. While it has seen off-label use as a purported cognitive enhancer to improve wakefulness, in animal and human studies the research on its effectiveness for this use is inconclusive. Modafinil is taken by mouth. It comes in oral tablet form of 100mg or 200mg. Clinical studies have not found evidence of diminished response or tolerance to modafinil's wakefulness-promoting properties at therapeutic doses over prolonged periods. In addition to its medical uses, modafinil has gained popularity among students, office workers, professionals, and others who seek enhanced wakefulness and cognitive function. However, studies have shown mixed results regarding its cognitive enhancement abilities.
|Trade names||Provigil, Alertec, Modavigil, others|
|Other names||CRL-40476; Diphenylmethyl-sulfinylacetamide|
|Very low to low|
|Drug class||CNS stimulant|
|Bioavailability||Not determined due to its aqueous insolubility|
|Metabolism||Liver (primarily via amide hydrolysis); CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5 involved|
|Elimination half-life||12-15 hours (modafinil, the racemic mixture),|
15 hours (armodafinil, the (R)-enantiomer),
4 hours (esmodafinil, the (S)-enantiomer).
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||273.35 g·mol−1|
|3D model (JSmol)|
While modafinil is generally well-tolerated when used according to proper dosing guidelines, it does carry potential risks and side effects that should be considered before use. Additionally, there are concerns about the potential abuse of modafinil due to its stimulant-like properties. Modafinil's side effects include headaches, anxiety, and nausea. Serious side effects in high doses include delusions, unfounded beliefs, paranoia, irrational thought, and transient depression, possibly due to its effects on dopamine receptors in the brain, as well as allergic reactions. The amount of medication used should be adjusted in those with kidney problems, as this medication has markedly increased side effects during renal insufficiency. It is not recommended in those with an arrhythmia, significant hypertension, or left ventricular hypertrophy. Modafinil appears to work by acting on dopamine and modulating the areas of the brain involved with the sleep cycle.
Originally developed in the 1970s by French neuroscientist Michel Jouvet and Lafon Laboratories, Modafinil has been prescribed in France since 1994, and was approved for medical use in the United States in 1998. Its legal status varies by jurisdiction; in the United States it is classified as a schedule IV controlled substance, whereas in the United Kingdom it is a prescription only medication. In some countries no controls apply. It is available as a generic medication. In 2020, modafinil was the 302nd most commonly prescribed medication in the United States, with just over 1000000 prescriptions. There are ongoing debates around using modafinil as a performance-enhancing drug or "smart drug", especially outside of medically approved uses like treating sleep disorders or ADHD. Some view its usage negatively due to ethical concerns about unfair advantages or reliance on drugs for improved productivity.
Sleep disorders edit
Modafinil is used primarily for the treatment of narcolepsy, shift work sleep disorder, and excessive daytime sleepiness associated with obstructive sleep apnea. For obstructive sleep apnea, it is recommended that patients use continuous positive airway pressure (CPAP) appropriately before they consider starting modafinil to help with daytime sleepiness. Because of the risk of development of skin or hypersensitivity reactions and serious adverse psychiatric reactions, the European Medicines Agency recommended that new patient prescriptions should be only to treat sleepiness associated with narcolepsy.
The UK National Institute for Health and Care Excellence (NICE) and MS NGOs suggest modafinil to help with multiple sclerosis (MS) fatigue off-label. Still, the results from two controlled studies are conflicting, given the lack of larger, long-term, randomized controlled studies.
Attention deficit hyperactivity disorder edit
Modafinil is sometimes prescribed off-label to people with attention deficit hyperactivity disorder (ADHD). However, there is a lack of research into modafinil for ADHD and, consequently, evidence supporting its use in adult ADHD compared to other treatments such as lisdexamfetamine.
Bipolar depression edit
A 2020 meta-analysis found that "augmentation with [modafinil or armodafinil] was associated with significantly greater rates of treatment response" in patients with bipolar depression "with no evidence of increased risk of mood switch or suicide attempts".
Modafinil was fielded to military personnel in the French Air Force, Foreign Legion, and Marine infantry during the Gulf War.
Adrafinil, a prodrug of modafinil, was first offered as an experimental treatment for narcolepsy in France in 1986. Modafinil, being more efficient than adrafinil, was deemed combat-worthy by the French Ministry of Defense in 1989 and was subsequently administered to personnel by their officers under the name Virgyl. This was done to improve a unit's "operational tempo", which refers to the rate at which military operations or activities are conducted. The goal was to enhance the unit's overall performance and efficiency. This evaluation took place before the introduction of modafinil on the market as medication in 1994, and the personnel involved were not informed of the product's nature. Later studies did not confirm the benefit of modafinil in military contexts that do not involve sleep deprivation.
Since then, armed forces of several countries, including the United States, the United Kingdom, India, and France, have expressed interest in modafinil as an alternative to amphetamine—the drug traditionally employed in combat situations or lengthy missions in which troops face sleep deprivation. The French government indicated that the Foreign Legion used modafinil during certain covert operations. The United Kingdom's Ministry of Defence commissioned research into modafinil from QinetiQ and spent £300,000 on one investigation. In 2011, the Indian Air Force announced that modafinil was included in contingency plans.
In the United States military, modafinil has been approved for use on certain Air Force missions, and it was investigated for other military uses. In 2012, modafinil was the only drug approved by the Air Force as a "go pill" for fatigue management (replacing prior use of amphetamine-based medications such as dextroamphetamine).
The Canadian Medical Association Journal reports that modafinil is used by astronauts on long-term missions aboard the International Space Station. Modafinil is "available to crew to optimize performance while fatigued" and helps with the disruptions in circadian rhythms and with the reduced quality of sleep astronauts experience.
The use of modafinil in military contexts that do not involve sleep deprivation is not recommended due to limited evidence on its effectiveness as a cognitive enhancer for non-sleep-deprived individuals. Additionally, there are potential risks of abuse, overconfidence, and negative impact on physical performance associated with modafinil use outside the context of sleep deprivation.
Modafinil has been used non-medically as a "smart drug" by students, office workers, transhumanists, professionals in the corporate and tech fields, surgeons, truck drivers, and call-center workers. Its attention-promoting, cognitive-enhancing, and wakefulness-boosting properties are cited by those people as reasons behind modafinil's use. However, multiple studies have consistently shown that modafinil does not provide cognitive enhancement or attention improvement benefits in non-sleep-deprived individuals, with some studies even reporting impairments in certain cognitive functions.
Available forms edit
Drug tolerance edit
Large-scale clinical studies have not found evidence of diminished response (drug tolerance) to modafinil's pro-wakefulness and anti-fatiguing properties at therapeutic doses over periods as long as three years.
Modafinil is contraindicated in people with known hypersensitivity to modafinil or armodafinil. Modafinil is not approved for use in children for any medical conditions, in whom there is a higher risk of rare but serious dermatological toxicity.
Due to limited available information on the excretion of modafinil into breastmilk and its potential effects on infants, careful monitoring of the infant is recommended when breastfeeding mothers use modafinil or considering alternative drugs may be preferred until more safety data are available.
Adverse effects edit
The incidence of adverse effects are reported as the following: less than 10% of users report having a headache, nausea, and decreased appetite. Between 5% and 10% of users may be affected with anxiety, insomnia, dizziness, diarrhea, and rhinitis. Modafinil-associated psychiatric reactions have occurred in those with and without a preexisting psychiatric history. No clinically significant changes in body weight have been observed with modafinil in clinical trials, although decreased appetite and weight loss have been reported with modafinil in children and adolescents probably due to the much higher modafinil exposure in these individuals based on body weight (i.e., mg/kg doses).
Rare occurrences have been reported of more serious adverse effects, including severe skin rashes and other symptoms that are probably allergy-related. From the date of initial marketing, December 1998, to January 30, 2007, the US Food and Drug Administration received six cases of severe cutaneous adverse reactions associated with modafinil, including erythema multiforme (EM), Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS syndrome, involving adult and pediatric patients. The FDA issued a relevant alert. In the same alert, the FDA also noted that angioedema and multi-organ hypersensitivity reactions have also been reported in postmarketing surveillance experiences which means adverse effects or reactions that have been reported after the drug was approved and made available on the market, indicating incidents that occurred in real-world use rather than just clinical trials.
In 2007, the FDA ordered Cephalon to modify the Provigil leaflet to add in bold-face print several serious and potentially fatal conditions attributed to modafinil use, including TEN, DRESS syndrome, and SJS.
The long-term safety and effectiveness of modafinil have not been determined. However, a longitudinal study in pediatric patients treated for narcolepsy for up to ten years demonstrated that modafinil and armodafinil were safe and effective, with the study concluding that use of modafinil and armodafinil significantly improved patients' ability to stay awake and did not exacerbate preexisting psychiatric conditions.
Addiction and dependence edit
The addiction and dependence liabilities of modafinil are very low. Modafinil shares biochemical mechanisms with addictive stimulant drugs, and some studies reported it to have similar mood-elevating properties, although to a lesser degree. It is not clear whether these effects are different from those from caffeine. Modafinil does not appear to produce euphoric effects nor deviations (i.e., abuse) from dosages assigned to the patient. Still, caution should be taken, because in clinical trials modafinil produced euphoric and psychoactive effects, altering thinking, mood, feelings, and perception like other CNS stimulants, so the risk of potential abuse still has to be assessed, the risk of potential abuse, as there are indications that modafinil may work on the same neurobiological mechanisms as other addictive stimulants.
Modafinil is classified by the United States Drug Enforcement Administration as a schedule IV controlled substance, a category for drugs with valid medical uses and low addiction potential. The International Narcotics Control Board does not consider modafinil a narcotic nor a psychotropic substance. Modafinil may increase abstinence rates in a subgroup of cocaine addicts, and modafinil-related discontinuation adverse effects are no different from placebo.
In mice and rats, the median lethal dose (LD50) of modafinil is approximately or slightly greater than 1250 mg/kg. Oral LD50 values for rats range from 1000 to 3400 mg/kg. Intravenous LD50 for dogs is 300 mg/kg. Clinical trials on humans involve taking up to 1200 mg/day for 7–21 days. Known incidents of acute one-time overdoses up to 4500 mg did not appear to cause life-threatening effects, although a number of adverse experiences were observed, including excitation or agitation, insomnia, anxiety, irritability, aggressiveness, confusion, nervousness, tremor, palpitations, sleep disturbances, nausea, and diarrhea. In 2005, the FDA was not aware of any fatal overdoses involving modafinil alone (as opposed to multiple drugs including modafinil).
Modafinil is a weak to moderate inducer of CYP3A4 and a weak inhibitor of CYP2C19, enzymes of the cytochrome P450 group of enzymes. Modafinil also induces or inhibits other cytochrome P450 enzymes. One in vitro study predicts that modafinil may induce the cytochrome P450 enzymes CYP1A2, CYP3A4, and CYP2B6, as well as may inhibit CYP2C9 and CYP2C19. However, other in-vitro studies find no significant inhibition of CYP2C9. Modafinil may induce P-glycoprotein, which may affect drugs transported by P-glycoprotein, such as digoxin. Therefore, modafinil affects pharmacodynamics of drugs which are metabolized by CYP3A4 and other enzymes of the cytochrome P450 family.
- opioids, such as methadone, hydrocodone, oxycodone, or fentanyl - modafinil may result in a drop in opioid plasma concentrations because of faster clearance by CYP3A4. If the patient is not monitored closely, reduced efficacy or withdrawal symptoms can occur.
- steroid hormones, such as estradiol, progesterone or cortisol. Modafinil may have an adverse effect on hormonal contraceptives for up to a month after discontinuation. In a 2006 study, a single dose of modafinil 200 mg caused a decrease in blood prolactin levels, although it did not affect human growth hormone or thyroid-stimulating hormone. Since modafinil induces the activity of the CYP3A4 enzyme involved in cortisol clearance, modafinil may reduce the bioavailability of hydrocortisone. Therefore, it may be necessary to adjust the steroid substitution dose in subjects receiving CYP3A4-metabolism-inducing drugs such as modafinil.
|DATTooltip Dopamine transporter||1.8–2.6 μM
|NETTooltip Norepinephrine transporter||>10 μM
|SERTTooltip Serotonin transporter||>10 μM
|Footnotes: a = Functional activity, not binding inhibition. b = Armodafinil at D2High. Notes: No activity at a variety of other assessed targets.|
Mechanism of action edit
The precise therapeutic mechanism of action of modafinil for narcolepsy and sleep-wake disorders remains unknown, however, the effect seems to be caused by binding of modafinil to the dopamine transporter and inhibiting dopamine reuptake. Modafinil acts as an atypical, selective, and weak dopamine reuptake inhibitor and indirectly activates the release of orexin neuropeptides and histamine from the lateral hypothalamus and tuberomammillary nucleus, all of which may contribute to heightened arousal.
Dopamine reuptake inhibitor edit
Modafinil elevates dopamine levels in the hypothalamus in animals. The locus of the monoamine action of modafinil was also studied, with effects identified on dopamine in the striatum and, in particular, nucleus accumbens, norepinephrine in the hypothalamus and ventrolateral preoptic nucleus, and serotonin in the amygdala and frontal cortex. Modafinil was screened at a large panel of receptors and transporters in an attempt to elucidate its pharmacology. Of the sites tested, it was observed to significantly affect only the dopamine transporter (DAT), acting as a dopamine reuptake inhibitor (DRI) with an IC50 value of 4 μM. Modafinil binds to the same site on the DAT as cocaine, but in a different manner. Modafinil increases locomotor activity and extracellular dopamine concentrations in animals in a manner similar to the selective DRI vanoxerine (GBR-12909), and also inhibits methamphetamine-induced dopamine release (a common property of DRIs, since DAT transport facilitates methamphetamine's access to its intracellular targets). As such, "modafinil is an exceptionally weak, but apparently very selective, [DAT] inhibitor". In addition to animal research, a human positron emission tomography (PET) imaging study observed that 200 mg and 300 mg doses of modafinil resulted in DAT occupancy of 51.4% and 56.9%, respectively, which is "close to that of methylphenidate". Another human PET imaging study similarly observed that modafinil occupied the DAT and also determined that it significantly elevated extracellular levels of dopamine in the brain, including in the nucleus accumbens.
Modafinil has been described as an "atypical" DAT inhibitor, and shows a profile of effects that is very different from those of other dopaminergic stimulants. For instance, modafinil produces wakefulness reportedly without the need for compensatory sleep, and shows relatively low, if any, potential for abuse. Aside from modafinil, other atypical DAT inhibitors include vanoxerine and benztropine, which have a relatively low abuse potential similar to modafinil. These drugs appear to interact with the DAT in a distinct way from "conventional" DAT blockers such as cocaine and methylphenidate. Analogues of modafinil with modafinil-like versus cocaine-like dopamine reuptake inhibition and effects have been synthesized.
Dopamine transporter-independent actions edit
Evidence against the hypothesis that modafinil exerts its effects by acting as a DRI is that tyrosine hydroxylase inhibitors (which deplete dopamine) fail to block the effects of modafinil in animals. Modafinil fails to reverse reserpine-induced akinesia, whereas dextroamphetamine, a dopamine releasing agent (DRA), is able to do so. One of the first published structure–activity relationship studies of modafinil found that DAT inhibition did not correlate with wakefulness-promoting effects in animals among modafinil analogues. A variety of analogues without significant DAT inhibition still produce wakefulness-promoting effects. "[The] neurochemical effects [of modafinil] and anatomical pattern of brain area activation differ from typical psychostimulants and are consistent with its beneficial effects on cognitive performance processes such as attention, learning, and memory". Another study found that modafinil-induced increased locomotor activity in animals was dependent on histamine release and could be abolished by depletion of neuronal histamine, whereas those of methylphenidate were not and could not be. Taken together, although it is established that modafinil is a clinically significant DRI, its full pharmacology remains unclear, and may include DAT-independent actions. One such action may be activation of the orexin system.
There is nonetheless evidence that modafinil produces at least some of its wakefulness-promoting effects by acting as a DRI, or at least via activation of the dopaminergic system. In support of the hypothesis that modafinil acts as a dopaminergic agent, its wakefulness-promoting effects are abolished in DAT knockout mice (although DAT knockout mice show D1 and D2 receptor and norepinephrine compensatory abnormalities that might confound this finding), reduced by both D1 and D2 receptor antagonists (although conflicting reports exist), and completely blocked by simultaneous inactivation of both D1 and D2 receptors. Modafinil shows full stimulus generalization (ability to produce similar effects or responses) to other DAT inhibitors including cocaine, methylphenidate, and vanoxerine, and discrimination (ability to differentiate or distinguish between different drugs) is blocked by administration of both ecopipam (SCH-39166), a D1 receptor antagonist, and haloperidol, a D2 receptor antagonist. Partial substitution (a phenomenon where a substance or drug partially replaces or mimics the effects of another substance or drug) was seen with the DRA dextroamphetamine and the D2 receptor agonist PNU-91356A, as well as with nicotine (which indirectly elevates dopamine levels through activation of nicotinic acetylcholine receptors).
Modafinil may have an additional mechanism of action: Both modafinil and its metabolite, modafinil sulfone, possess anticonvulsant properties in animals, and modafinil sulfone is nearly as potent as modafinil in producing this effect. However, modafinil sulfone lacks wakefulness-promoting effects in animals, indicating that a distinct mechanism may be at play in the anticonvulsant effects of both compounds.
Dopamine D2 receptor partial agonist edit
Armodafinil, the (R)-enantiomer of modafinil, acts as a D2High receptor partial agonist, with a Ki of 16 nM, an intrinsic activity of 48%, and an EC50 of 120 nM, in rat striatal tissue. Esmodafinil, the (S)-enantiomer of modafinil, is inactive with respect to the D2 receptor. Modafinil directly inhibits the firing of midbrain dopaminergic neurons in the ventral tegmental area and substantia nigra of rats via activation of D2 receptors. However, modafinil seems not to interact with the human D2 receptor (Ki = >10 μM).
Dampening of amygdala activity edit
There is some mouse and human evidence (via direct fMRI observation and anxiety questionnaires) to suggest that modafinil may reduce amygdala activity. The amygdala is involved in fear processing, and the dampening of its activity reduces perceptions of fear in response to environmental stress. One study documented a statistically significant reduction in fear response among human subjects given 100 mg of modafinil daily for 7 days. However, another study investigating the acute effects of modafinil on fear processing reported an increase in amygdala responses to fearful faces after administration of 600 mg of modafinil in human subjects. Modafinil's dose dependent effects on fear processing may exhibit a Yerkes–Dodson relationship.
Cmax (peak levels) occurs approximately 2 to 3 hours after modafanil administration. Food slows absorption of modafanil, but does not affect the total AUC. In vitro measurements indicate that 60% of modafinil is bound to plasma proteins at clinical concentrations of the drug. This percentage changes very little when the concentration of modafinil is varied.
Renal excretion of unchanged modafinil usually accounts for less than 10% of an oral dose. This means that when modafinil is taken by mouth, less than 10% of the drug is eliminated from the body through the urine without being metabolized (broken down) by the liver or other organs. The rest of the drug is either metabolized or excreted through other routes, such as feces or bile. The two major circulating metabolites of modafinil are modafinil acid (CRL-40467) and modafinil sulfone (CRL-41056). Both of these metabolites have been described as inactive, and neither appears to contribute to the wakefulness-promoting effects of modafinil. However, modafinil sulfone does appear to possess anticonvulsant effects, a property that it shares with modafinil.
Elimination half-life is in the range of 10 to 12 hours, subject to differences in cytochrome P450 genotypes, liver function, and renal function. Modafinil is metabolized mainly in the liver, and its inactive metabolite is excreted in the urine. Urinary excretion of the unchanged drug is usually less than 10%, but can range from 0% to as high as 18.7%, depending on the factors mentioned.
Detection in body fluids edit
Modafinil and/or its major metabolite, modafinil acid, may be quantified in plasma, serum, or urine to monitor dosage in those receiving the drug therapeutically, to confirm a diagnosis of poisoning in hospitalized patients, or to assist in the forensic investigation of a vehicular traffic violation. Instrumental techniques involving gas or liquid chromatography are usually employed for these purposes. In 2011, modafinil was not tested for by common drug screens (except for anti-doping screens) and is unlikely to cause false positives for other chemically unrelated drugs such as substituted amphetamines.
|Modafinil||Yellow/Orange > Brown||Darkening Orange||Deep orange/red|
Structural analogues edit
Many derivatives and structural analogues of modafinil have been synthesized and studied. Examples include adrafinil, CE-123, fladrafinil (CRL-40941; fluorafinil), flmodafinil (CRL-40940; bisfluoromodafinil, lauflumide), and modafinil sulfone (CRL-41056).
Modafinil was originally developed in France by Neurophysiology professor Michel Jouvet and Lafon Laboratories. Modafinil was among a series of benzhydryl sulfinyl compounds invented in the 1970s, including adrafinil, which was first offered as an experimental treatment for narcolepsy in France in 1986. Modafinil is the primary metabolite of adrafinil, lacking the polar -OH group on its terminal amide, and has similar activity to the parent drug. Modafinil has been prescribed in France since 1994 under the name Modiodal, and in the US since 1998 as Provigil. In contrast, adrafinil does not have FDA approval, and it was marketed in France until 2011 and then withdrawn.
In 1998, modafinil was approved by the US Food and Drug Administration for the treatment of narcolepsy and in 2003, for shift work sleep disorder and obstructive sleep apnea/hypopnea even though caffeine and amphetamine were shown to be more wakefulness promoting on the Stanford Sleepiness Test Score than modafinil.
Modafinil was approved for use in the UK in December 2002. Modafinil is marketed in the United States by Cephalon, who originally leased the rights from Lafon, but eventually purchased the company in 2001.
Cephalon began to market armodafinil, the (R)-enantiomer of modafinil, in the United States in 2007. After protracted patent litigation and negotiations (see below), generic versions of modafinil became available in the US in 2012.
Patent protection and litigation edit
U.S. Patent 4,927,855 was issued to Laboratoire L. Lafon on May 22, 1990, covering the chemical compound modafinil. After receiving an interim term extension of 1066 days and pediatric exclusivity of six months, the patent expired on October 22, 2010.
On October 6, 1994, Cephalon filed an additional patent, covering modafinil in the form of particles of defined size. That patent, U.S. Patent 5,618,845 was issued on April 8, 1997. It was reissued in 2002 as RE 37,516, which surrendered the 5618845 patent. With pediatric exclusivity, this patent expired on April 6, 2015.
On December 24, 2002, anticipating the expiration of exclusive marketing rights, generic drug manufacturers Mylan, Teva, Barr, and Ranbaxy applied to the FDA to market a generic form of modafinil. At least one withdrew its application after early opposition by Cephalon based on the RE 37,516 patent. There is uncertainty about whether a particle size patent is sufficient protection against the manufacture of generics: including whether modafinil may be modified or manufactured to avoid the granularities specified in the new Cephalon patent, and whether patenting particle size is invalid because particles of appropriate sizes are likely to be obvious to practitioners skilled in the art. However, under United States patent law, a patent is entitled to a legal presumption of validity, meaning that in order to invalidate the patent, much more than "pertinent questions" of this sort are required.
On October 31, 2011, US Reissue Patent No. RE 37,516 was declared invalid and unenforceable. The District Court for the Eastern District of Pennsylvania ruled that RE 37,516 was invalid because it: (1) was on sale more than one year prior to the date of the application in violation of 35 U.S.C. section 102(b); (2) was actually invented by someone else (the French company Laboratoire L. Lafon); (3) was obvious at the time the invention was made to a person having ordinary skill in the art under 35 U.S.C. section 103(a); and (4) failed the written description requirement of 35 U.S.C. section 112. The patent was also found to be unenforceable due to Cephalon's inequitable conduct during patent prosecution.
Cephalon made an agreement with four major generics manufacturers Teva, Barr Pharmaceuticals, Ranbaxy Laboratories, and Watson Pharmaceuticals between 2005 and 2006 to delay sales of generic modafinil in the US until April 2012 by these companies in exchange for upfront and royalty payments.
This agreement was challenged by a class of wholesalers who bought Provigil directly from Cephalon, who claimed that Cephalon and the generic manufacturers conspired to keep the modafinil price artificially high and violated antitrust laws. The plaintiffs brought a case to the United States District Court for the Eastern District of Pennsylvania in 2006. They alleged that Cephalon, the patent holder of Provigil, and four generic drug manufacturers (Teva, Ranbaxy, Mylan, and Barr) entered into unlawful reverse payment settlements that delayed the entry of generic modafinil into the market and maintained Cephalon's monopoly. The plaintiffs claimed that they paid artificially inflated prices for Provigil due to the anticompetitive agreements. The plaintiffs sought damages and injunctive relief under the Sherman Act and various state laws. The district court dismissed the plaintiffs' claims in 2015, finding that they failed to allege that the settlements were anticompetitive plausibly. The court applied the rule of reason analysis, which weighs the procompetitive and anticompetitive effects of an agreement, and concluded that the plaintiffs did not show that the generic manufacturers would have entered the market earlier absent the settlements or that the patent was invalid or not infringed. The court also found that the settlements had some procompetitive benefits, such as allowing early entry of generic modafinil before the patent expired and providing compensation to consumers. The plaintiffs appealed to the Third Circuit Court of Appeals, which affirmed the district court's decision in 2016. Therefore, the court concluded that the settlements did not violate antitrust laws.
Apotex received regulatory approval in Canada despite a suit from Cephalon's marketing partner in Canada, Shire Pharmaceuticals. Cephalon sued Apotex in the US to prevent it from releasing a genericized armodafinil (Nuvigil). Cephalon's 2011 attempt to merge with Teva was approved by the FTC under a number of conditions, including granting generic US rights to another company; ultimately, Par Pharmaceutical acquired the US modafinil rights as well as some others.
Society and culture edit
Legal status edit
In Australia, modafinil is considered to be a Schedule 4 prescription-only medicine or prescription animal remedy. Schedule 4 is defined as "Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription."
In mainland China, modafinil is strictly controlled like other stimulants such as amphetamines and methylphenidate. It is classified as Class I psychotropic drug, meaning that only doctors who have the right to prescribe narcotics and Class I psychotropic drugs (usually through special examination) can prescribe it, for no more than three-day use (or seven-day use for control/extend-release products).
In The Republic of Moldova, modafinil is considered a psychotropic drug but can be purchased with prescription, however, importing modafinil may be considered illegal psychotropic drug (narcotics) trafficking and can be punished by up to 8 years in prison, as warned by the Customs service of Moldova. In order to determine the punishment, the quantities of up to 0,002g of modafinil are considered "small quantities", while quantities in the range of 0,002g to 1,0g are considered "large quantities". In Transnistria, modafinil is a prohibited substance (similar to narcotics) regardless of prescription and possession of even a few pills can lead to imprisonment.
In Japan, modafinil is Schedule I psychotropic drug. Cephalon licensed Alfresa Corporation to produce, and Mitsubishi Tanabe Pharma to sell modafinil products under the trade name Modiodal in Japan. There have been arrests of people who imported modafinil for personal use.
Modafinil is considered a stimulant doping agent and, as such, is prohibited in sports competitions. It is in the same category as steroids. Due to laws passed in 2022, import into the country or selling is considered a felony and can be punished with jail time from three to seven years. Simple possession for personal use is punished with a fine and confiscation.
In Sweden, modafinil is classified as a schedule IV substance; possession is illegal without prescription.
United States edit
Modafinil is classified as a Schedule IV controlled substance under United States federal law. It is illegal to import by anyone other than a DEA-registered importer without a prescription. The Clinton administration issued regulations in 64 FR 4050 effective January 27, 1999, based upon a recommendation of the administration's Assistant Secretary for Health.
A person may legally bring modafinil into the United States in person from a foreign country, provided that the person has a prescription for it, and the drug is properly declared at the border crossing. US residents are limited to 50 dosage units (e.g., pills). Under the US Pure Food and Drug Act, drug companies are not allowed to market their drugs for off-label uses (treatments of conditions other than those officially approved by the FDA); Cephalon was reprimanded in 2002 by the FDA because its promotional materials were found to be "false, lacking in fair balance, or otherwise misleading". Cephalon pleaded guilty to a criminal violation and paid several fines, including $50 million and $425 million fines to the US government in 2008.
Other countries edit
The following countries do not classify modafinil as a controlled substance:
- In Finland, modafinil is a prescription drug but not listed as a controlled substance.
- In Denmark, modafinil is a prescription drug but not listed as a controlled substance.
- Mexico (Not listed as a controlled substance, in the National Health Law. Can be purchased in pharmacies without prescription.)
- South Africa Schedule V
- United Kingdom (not listed in Misuse of Drugs Act so possession is not illegal, but a prescription is required) 
Brand names edit
Modafinil is sold under a variety of brand names worldwide, including Alertec, Alertex, Altasomil, Aspendos, Bravamax, Forcilin, Intensit, Mentix, Modafinil, Modafinilo, Modalert, Modanil, Modasomil, Modvigil, Modiodal, Modiwake, Movigil, Provigil, Resotyl, Stavigile, Vigia, Vigicer, Vigil, Vigimax, Waklert, and Zalux.
The global sales figures for modafinil are not known, still, Modafinil sold under the brand name Provigil accounted for over 40% of Cephalon's global turnover for several years, according to the information published in 2020.
The price of modafinil in some English-speaking countries is the following:
- USA: The cost for modafinil 200 mg tablets is around $217 for a supply of 20 tablets, prices start at $28.61.
- UK: The cost of modafinil 100mg tablets is £18.05 for a supply of 20 tablets.
- Canada: Most pharmacies will charge an arm and a leg for brand name modafinil — which can be as high as $65 CAD for a supply of 20 tablets of 100 mg.
- Australia: The cost of modafinil 100mg is $110.99 for a supply of 60 tablets.
The regulation of modafinil as a doping agent has been controversial in the sporting world, with high-profile cases attracting press coverage since several prominent American athletes tested positive for the substance. Some athletes who used modafinil protested that the drug was not on the prohibited list at the time of their offenses. However, the World Anti-Doping Agency (WADA) maintains that modafinil was related to already-banned substances. The Agency added modafinil to its list of prohibited substances on August 3, 2004, ten days before the start of the 2004 Summer Olympics.
Several athletes (such as sprinter Kelli White in 2003, cyclist David Clinger and basketball player Diana Taurasi in 2010, and rower Timothy Grant in 2015) were accused of using modafinil as a performance-enhancing doping agent. Taurasi and another player—Monique Coker, tested at the same lab—were later cleared. Kelli White, who tested positive after her 100m victory at the 2003 World Championships in Paris, was stripped of her gold medals. She claimed that she used modafinil to treat narcolepsy, but the International Association of Athletics Federations (IAAF) ruled that modafinil was a performance-enhancing drug.
The BALCO scandal brought to light an unsubstantiated (but widely published) account of Major League Baseball's all-time leading home-run hitter Barry Bonds' supplemental chemical regimen that included modafinil in addition to anabolic steroids and human growth hormone.
In a study on 15 healthy male subjects, published in Medicine & Science in Sports & Exercise, an academic journal, acute ingestion of modafinil of 4 mg·kg−1 (at a dose of 4 mg per kilogram of body weight), prolonged exercise time to exhaustion while performing at 85% of VO2max threshold, and also reduced the perception of effort required to maintain this threshold,  i.e., the control subjects were able to perform at 85% of their maximum oxygen consumption without feeling as much effort as without modafinil (with placebo).
Social views edit
The use of modafinil as a supposed cognitive enhancer is viewed differently among various groups. Some groups consider such use as cheating, unnatural, or risky. For instance, some academic institutions such as University of Sussex in the UK have explored this question raised by the students, although the university do not have a strong, official stance on its use, explaining that it is a prescription drug and the decision should be made by the doctor on whether to prescribe modafinil to a student. In the realm of bioethics, the President's Council on Bioethics in the US, chaired by Leon Kass, argued that excellence achieved through the use of drugs like modafinil is "cheap" as it obviates the need for hard work and study, and is not fully authentic because the excellence is partly attributable to the drug, not the individual. On the other hand, some people, particularly those in high-pressure environments like Wall Street traders, do not view the use of modafinil as cheating. They argue that if modafinil can give them an edge and they are aware of the risks involved, it should not be considered as cheating. Due to such varying views, modafinil users for nacrolepsy may cope with stigma by hiding, denying, or justifying their use, or by seeking support from others who share their views or experiences.
Music and entertainment edit
Peter Cullen, is an American-Canadian voice actor, wrote "Modafinil - Music to Mod to", an instrumental electronic composition influenced by modafinil. Matthew Dear an American electronic music producer and DJ, wrote "Modafinil Blues", an indie rock song. Joe Rogan, an American comedian, podcaster, and mixed martial arts commentator, has talked about modafinil on his show The Joe Rogan Experience.
Psychiatric conditions edit
Major depression edit
Modafinil has been studied in the treatment of major depressive disorder. In a 2021 systematic review and meta-analysis of randomized controlled trials of psychostimulants for depression, modafinil and other stimulants such as methylphenidate and amphetamines improved depression in traditional meta-analysis. However, when subjected to network meta-analysis, modafinil and most other stimulants did not significantly improve depression, with only methylphenidate remaining effective. Modafinil and other stimulants likewise did not improve quality of life in the meta-analysis, although there was evidence for reduced fatigue and sleepiness with modafinil and other stimulants. While significant effectiveness of modafinil for depression has been reported, reviews and meta-analyses note that the effectiveness of modafinil for depression is limited, the quality of available evidence is low, and the results are inconclusive.
Bipolar depression edit
Modafinil and armodafinil have been repurposed as adjunctive treatments for acute depression in people with bipolar disorder. A 2021 meta-analysis concluded that add-on modafinil and armodafinil were more effective than placebo on response to treatment, clinical remission, and reduction in depressive symptoms, with only minor side effects, but the effect sizes are small and the quality of evidence is therefore low, limiting the clinical relevance of the evidence. Very low rates of mood switch (a change in mood from one extreme to another) have been observed with modafinil and armodafinil in bipolar disorder.
Attention deficit hyperactivity disorder edit
Modafinil was seriously considered for the treatment of attention deficit hyperactivity disorder (ADHD) because of its lower abuse potential than conventional psychostimulants like methylphenidate and amphetamines. In 2008, an application to market modafinil for pediatric ADHD was submitted to the Food and Drug Administration in the USA.
However, evidence of modafinil for treatment of adult ADHD is mixed, and a 2016 systematic review of alternative drug therapies for adult ADHD did not recommend its use in this context. In a later large phase 3 clinical trial of modafinil for adult ADHD, modafinil was not effective in improving symptoms, and there was a high rate of side effects (86%) and discontinuation (47%). The poor tolerability of modafinil in this study was possibly due to the use of excessively high doses (210–510 mg/day). Another reason for the denial of the approval was due to concerns about rare but serious dermatological toxicity (Stevens–Johnson syndrome).
Substance dependence edit
Treatment of cocaine addiction edit
Modafinil has been studied for the treatment of cocaine addiction. Modafinil binds to the dopamine transporter (DAT) in an open-to-out conformation, differently than cocaine and methylphenidate. Subjects pretreated with modafinil report experiencing less euphoria from cocaine administration. Modafinil does not potentiate self-administration of cocaine in pretreated rats.
The mechanism by which modafinil inhibits cocaine self-administration is likely more complex than the simple observation that modafinil occupies the DAT, as drugs like methylphenidate (another dopamine re-uptake inhibitor (DRI) fail to reduce cocaine self-administration. Atypical DRIs like modafinil that bind to the DAT in an open-to-out conformation often lack abuse potential relative to cocaine-like DAT ligands.
Modafinil and armodafinil were studied as a complement to antipsychotic medications in the treatment of schizophrenia. They showed no effect on positive symptoms or cognitive performance. A 2015 meta-analysis found that modafinil and armodafinil may slightly reduce negative symptoms in people with acute schizophrenia, though they do not appear useful for people with the condition who are stable, with high negative symptom scores. Among medications demonstrated to be effective for reducing negative symptoms in combination with antipsychotics, modafinil and armodafinil are among the smallest effect sizes.
Cognitive enhancement edit
A 2015 review of clinical studies of possible nootropic effects in healthy people found: "...whilst most studies employing basic testing paradigms show that modafinil intake enhances executive function, only half show improvements in attention and learning and memory, and a few even report impairments in divergent creative thinking. In contrast, when more complex assessments are used, modafinil appears to consistently engender enhancement of attention, executive functions, and learning. Importantly, we did not observe any preponderances for side effects or mood changes." A 2019 review of studies of a single-dose of modafinil on mental function in healthy, non-sleep-deprived people found a statistically significant but small effect and concluded that the drug has limited usefulness as a cognitive enhancer in non-sleep-deprived persons. A 2020 review of the cognitive enhancing potential of methylphenidate, d-amphetamine, and modafinil in healthy individuals across various domains found that modafinil has a small, positive effect on memory updating.
Post-anesthesia sedation edit
General anesthesia is required for many surgeries, but may cause lingering fatigue, sedation, and/or drowsiness after surgery that lasts for hours to days. In outpatient settings in which patients are discharged home after surgery, this sedation, fatigue, and occasional dizziness is problematic, but it was only tested in one small study, and the results are inconclusive.
Modafinil was studied for use in multiple sclerosis-associated fatigue, but the resulting evidence was weak and inconclusive. There were two small controlled studies with conflicting results, and no large, long-term, randomized controlled studies. Therefore, the benefit of using modafinil for the treatment of multiple sclerosis-related fatigue was not confirmed.
Postural orthostatic tachycardia syndrome edit
Caution should be exercised in patients who have narcolepsy in comorbidity with postural orthostatic tachycardia syndrome (POTS). Modafinil, like other centrally acting stimulants prescribed for patients in narcolepsy, increases POTS-related autonomic dysfunction and results in tachycardia/arrhythmia side effects in patients with cardiovascular risk factors. Sodium oxybate, a metabolite of GABA, is an alternative drug for stimulant-intolerant patients with POTS.
One probable explanation of the drug's supposed anti-inflammatory properties is that that modafinil may modulate the production of nitric oxide in various cells, potentially leading to anti-inflammatory effects. Nitric oxide is a signaling molecule that plays a complex role in inflammation. It is produced by a variety of cells in the body, including immune cells, and can have both pro-inflammatory and anti-inflammatory effects depending on the context. In a 2018 study, researchers noticed that modafinil reduced the production of pro-inflammatory cytokines in vitro in mouse brain cells. In a 2020 study, scholars observed modafinil reduced inflammation and oxidative stress in the brains of rats with traumatic brain injury. In a 2023 study, modafinil reduced neuroinflammation in rats induced by propionic acid.
Another probable explanation is that modafinil may exert anti-inflammatory effects by upregulating adenosine A2A and A2B receptors. These receptors activate cyclic adenosine monophosphate signaling, which suppresses inflammation and fibrosis. This suggests that modafinil's ability to upregulate these receptors may serve as a potential therapy for fibrotic diseases. In a 2020 in vitro study, using in nonalcoholic hepatitis human cell model, the authors predicted that modafinil may reduce inflammatory and fibrotic progression in the human liver.
The results of studies on the potential anti-inflammatory properties of modafinil still need to be more conclusive.
- Mignot EJ (October 2012). "A practical guide to the therapy of narcolepsy and hypersomnia syndromes". Neurotherapeutics. 9 (4): 739–752. doi:10.1007/s13311-012-0150-9. PMC 3480574. PMID 23065655.
Because of the relatively low risk of addiction, modafinil can be more easily prescribed in patients without a clear, biochemically defined central hypersomnia syndrome, and is also easier to stop, if needed. It is also a schedule IV compound.
- Krishnan R, Chary KV (2015). "A rare case modafinil dependence". Journal of Pharmacology & Pharmacotherapeutics. J Pharmacol Pharmacotherapy. 6 (1): 49–50. doi:10.4103/0976-500X.149149. PMC 4319252. PMID 25709356.
- "Modafinil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on March 30, 2019. Retrieved June 24, 2018.
- Anvisa (March 31, 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published April 4, 2023). Archived from the original on August 3, 2023. Retrieved August 3, 2023.
- "Modafinil Product information". Health Canada. April 25, 2012. Archived from the original on June 10, 2022. Retrieved June 10, 2022.
- "Provigil- modafinil tablet". DailyMed. November 30, 2018. Archived from the original on June 10, 2022. Retrieved June 10, 2022.
- Robertson P, Hellriegel ET (2003). "Clinical pharmacokinetic profile of modafinil". Clin Pharmacokinet. 42 (2): 123–37. doi:10.2165/00003088-200342020-00002. PMID 12537513. S2CID 1266677.
- Darwish M, Kirby M, Hellriegel ET, Yang R, Robertson P (2009). "Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies". Clin Drug Investig. 29 (2): 87–100. doi:10.2165/0044011-200929020-00003. PMID 19133704. S2CID 24886727.
- "Nuvigil- armodafinil tablet". DailyMed. November 30, 2018. Archived from the original on August 16, 2022. Retrieved June 10, 2022.
- Robertson P, DeCory HH, Madan A, Parkinson A (June 2000). "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil". Drug Metabolism and Disposition. 28 (6): 664–671. PMID 10820139.
- "Provigil Prescribing Information" (PDF). United States Food and Drug Administration. Teva Pharmaceuticals USA, Inc. January 2015. Archived (PDF) from the original on February 17, 2017. Retrieved July 18, 2015.
- Greenblatt K, Adams N (February 2022). "Modafinil". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 30285371. Archived from the original on October 8, 2022. Retrieved October 9, 2022.
- Battleday RM, Brem AK (November 2015). "Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review". European Neuropsychopharmacology. 25 (11): 1865–1881. doi:10.1016/j.euroneuro.2015.07.028. PMID 26381811. S2CID 23319688.
- Meulen R, Hall W, Mohammed A (2017). Rethinking Cognitive Enhancement. Oxford University Press. p. 116. ISBN 9780198727392.
- "Study drugs make healthy people worse at problem-solving, not better". The Economist. ISSN 0013-0613. Retrieved November 25, 2023.
- BNF 74 (74 ed.). Pharmaceutical Press. September 2017. p. 468. ISBN 978-0857112989.
- Denis F (2021). "Smart drugs et nootropiques". Socio-anthropologie (43): 97–110. doi:10.4000/socio-anthropologie.8393. ISSN 1276-8707. S2CID 237863162.
- "Modafinil - Drug Usage Statistics". ClinCalc. Archived from the original on June 19, 2020. Retrieved October 7, 2022.
- Morgenthaler TI, Lee-Chiong T, Alessi C, Friedman L, Aurora RN, Boehlecke B, et al. (November 2007). "Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report". Sleep. 30 (11): 1445–1459. doi:10.1093/sleep/30.11.1445. PMC 2082098. PMID 18041479.
- Zee PC, Attarian H, Videnovic A (February 2013). "Circadian rhythm abnormalities". Continuum. 19 (1 Sleep Disorders): 132–147. doi:10.1212/01.CON.0000427209.21177.aa. PMC 3654533. PMID 23385698.
- European Medicines Agency, January 27, 2011, Questions and answers on the review of medicines containing Modafinil Archived August 9, 2017, at the Wayback Machine
- "Multiple sclerosis in adults: Management, Guidance". The National Institute for Health and Care Excellence (NICE). June 22, 2022. Archived from the original on September 5, 2022. Retrieved September 5, 2022.
- "Modafinil (Provigil) | MS Trust". Archived from the original on September 5, 2022. Retrieved September 5, 2022.
- "Provigil". National Multiple Sclerosis Society. Archived from the original on September 5, 2022. Retrieved September 6, 2022.
- Brown JN, Howard CA, Kemp DW (June 2010). "Modafinil for the treatment of multiple sclerosis-related fatigue". Ann Pharmacother. 44 (6): 1098–103. doi:10.1345/aph.1M705. PMID 20442351. S2CID 207263842.
- Wilms W, Woźniak-Karczewska M, Corvini PF, Chrzanowski Ł (October 2019). "Nootropic drugs: Methylphenidate, modafinil and piracetam - Population use trends, occurrence in the environment, ecotoxicity and removal methods - A review". Chemosphere. 233: 771–785. Bibcode:2019Chmsp.233..771W. doi:10.1016/j.chemosphere.2019.06.016. PMID 31200137. S2CID 189861826.
- Kittel-Schneider S, Quednow BB, Leutritz AL, McNeill RV, Reif A (May 2021). "Parental ADHD in pregnancy and the postpartum period - A systematic review" (PDF). Neuroscience and Biobehavioral Reviews. 124: 63–77. doi:10.1016/j.neubiorev.2021.01.002. PMID 33516734. S2CID 231723198.
- Weiergräber M, Ehninger D, Broich K (April 2017). "Neuroenhancement and mood enhancement – Physiological and pharmacodynamical background". Med Monatsschr Pharm. 40 (4): 154–64. PMID 29952165.
- Stuhec M, Lukić P, Locatelli I (February 2019). "Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis". The Annals of Pharmacotherapy. 53 (2): 121–133. doi:10.1177/1060028018795703. PMID 30117329. S2CID 52019992.
- Stuhec M, Lukić P, Locatelli I (February 2019). "Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis". Ann Pharmacother. 53 (2): 121–133. doi:10.1177/1060028018795703. PMID 30117329. S2CID 52019992.
- Nunez NA, Singh B, Romo-Nava F, Joseph B, Veldic M, Cuellar-Barboza A, et al. (March 2020). "Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials". Bipolar Disorders. 22 (2): 109–120. doi:10.1111/bdi.12859. PMID 31643130.
- "Les cobayes de la guerre du Golfe". Le Monde (in French). December 18, 2005. Archived from the original on April 10, 2021. Retrieved February 26, 2021.
- Van Puyvelde M, Van Cutsem J, Lacroix E, Pattyn N (January 2022). "A State-of-the-Art Review on the Use of Modafinil as A Performance-enhancing Drug in the Context of Military Operationality". Mil Med. 187 (1–2): 52–64. doi:10.1093/milmed/usab398. PMID 34632515.
- Martin R (November 1, 2003). "It's Wake-Up Time". Wired. ISSN 1059-1028. Retrieved May 23, 2019.
- Wheeler B (October 26, 2006). "BBC report on MoD research into modafinil". BBC News. Archived from the original on February 15, 2009. Retrieved July 4, 2012.
- "MoD's secret pep pill to keep forces awake". The Scotsman. February 27, 2005. Archived from the original on January 1, 2014.
- "Pilot pill project". Pune Mirror. February 16, 2011. Archived from the original on March 19, 2012. Retrieved July 4, 2012.
- Taylor GP Jr, Keys RE (December 1, 2003). "Memorandum for SEE distribution" (PDF). United States Department of the Air Force. Archived from the original (PDF) on June 12, 2009.
- "Air Force Special Operations Command Instruction 48–101" (PDF). November 30, 2012. Archived from the original (PDF) on April 10, 2018.
(sects. 1.7.4), U.S. Air Force Special Operations Command
- Thirsk R, Kuipers A, Mukai C, Williams D (June 2009). "The space-flight environment: the International Space Station and beyond". CMAJ. 180 (12): 1216–1220. doi:10.1503/cmaj.081125. PMC 2691437. PMID 19487390.
- Cadwalladr C (February 14, 2015). "Students used to take drugs to get high. Now they take them to get higher grades". The Guardian. Archived from the original on August 3, 2020. Retrieved January 7, 2017.
- Talbot M. "Brain Gain". The New Yorker. Retrieved April 9, 2017.
- "Super Soldiers? Military Drug New Rage". ABC News. December 7, 2008. Archived from the original on August 17, 2020. Retrieved June 28, 2020.
- "Like It or Not, "Smart Drugs" Are Coming to the Office". Harvard Business Review. May 2015.
- Plotz D (August 21, 2003). "Medikamente: 100 Milligramm Arbeitswut". Die Zeit. Archived from the original on November 30, 2019. Retrieved April 9, 2017.
- Van Rooyen LR, Gihwala R, Laher AE (May 2021). "Stimulant use among prehospital emergency care personnel in Gauteng Province, South Africa". South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde. 111 (6): 587–590. doi:10.7196/SAMJ.2021.v111i6.15465. PMID 34382572. S2CID 236402826.
- "Professors are taking the same 'smart drugs' as students to keep up with workloads". The Independent. May 30, 2017. Archived from the original on December 7, 2022. Retrieved January 17, 2023.
- Zamanian MY, Karimvandi MN, Nikbakhtzadeh M, Zahedi E, Bokov DO, Kujawska M, Heidari M, Rahmani MR (2023). "Effects of Modafinil (Provigil) on Memory and Learning in Experimental and Clinical Studies: From Molecular Mechanisms to Behaviour Molecular Mechanisms and Behavioural Effects". Curr Mol Pharmacol. 16 (4): 507–516. doi:10.2174/1874467215666220901122824. PMID 36056861. S2CID 252046371.
- Billiard M, Lubin S (2015). "Modafinil: Development and Use of the Compound". Sleep Medicine. New York, NY: Springer New York. pp. 541–544. doi:10.1007/978-1-4939-2089-1_61. ISBN 978-1-4939-2088-4.
- Nasr S, Wendt B, Steiner K (October 2006). "Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice". Journal of Affective Disorders. 95 (1–3): 111–114. doi:10.1016/j.jad.2006.01.010. PMID 16737742.
- Mitler MM, Harsh J, Hirshkowitz M, Guilleminault C (July 2000). "Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy". Sleep Medicine. 1 (3): 231–243. doi:10.1016/s1389-9457(00)00031-9. PMID 10828434.
- "Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group". Annals of Neurology. 43 (1): 88–97. January 1998. doi:10.1002/ana.410430115. PMID 9450772. S2CID 9526780.
- "FDA data on Modafinil" (PDF). Accessdata.fda.gov. 2010. Archived (PDF) from the original on November 11, 2020. Retrieved September 9, 2018.
- "FDA Provigil Drug Safety Data" (PDF). Fda.gov. January 2015. Archived (PDF) from the original on May 2, 2017.
- Sousa A, Dinis-Oliveira RJ (2020). "Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects". Substance Abuse. 41 (2): 155–173. doi:10.1080/08897077.2019.1700584. PMID 31951804. S2CID 210709160.
- Rugino T (June 2007). "A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents". Neuropsychiatric Disease and Treatment. 3 (3): 293–301. PMC 2654790. PMID 19300563.
- Modafinil. National Institute of Child Health and Human Development. 2006. PMID 30000988.
- "Australian Adverse Drug Reactions Bulletin 2008". Australian Adverse Drug Reactions Bulletin. December 1, 2008. Archived from the original on July 3, 2020.
- "Provigil" (PDF). Medication Guide. Cephalon, Inc. November 1, 2010. Archived from the original (PDF) on March 4, 2016. Retrieved December 31, 2013.
- Kumar R (2008). "Approved and investigational uses of modafinil : an evidence-based review". Drugs. 68 (13): 1803–1839. doi:10.2165/00003495-200868130-00003. PMID 18729534. S2CID 38542387.
- "Modafinil (marketed as Provigil): Serious Skin Reactions". Food and Drug Administration. 2007. Archived from the original on January 15, 2009.
- Henriksen K, Battles JB, Marks ES, Lewin DI, Chan AS, Martins SB, Coleman RW, Bosworth HB, Oddone EZ, Shlipak MG, Tu SW, Musen MA, Hoffman BB, Goldstein MK (2005). Post-fielding Surveillance of a Guideline-based Decision Support System. PMID 21249810.
- Banerjee D, Vitiello MV, Grunstein RR (October 2004). "Pharmacotherapy for excessive daytime sleepiness". Sleep Medicine Reviews. 8 (5): 339–354. doi:10.1016/j.smrv.2004.03.002. PMID 15336235.
- Ivanenko A, Kek L, Grosrenaud J (April 28, 2017). "0954 Long-Term Use of Modafinil and Armodafinil in Pediatric Patients with Narcolepsy". Sleep. 40 (suppl_1): A354–A355. doi:10.1093/sleepj/zsx050.953. ISSN 0161-8105. Archived from the original on June 8, 2021. Retrieved February 18, 2021.
- "Provigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. January 2015. Archived (PDF) from the original on February 17, 2017. Retrieved August 16, 2015.
- Kim D (February 22, 2012). "Practical use and risk of modafinil, a novel waking drug". Environmental Health and Toxicology. 27: e2012007. doi:10.5620/eht.2012.27.e2012007. PMC 3286657. PMID 22375280.
- Warot D, Corruble E, Payan C, Weil JS, Puech AJ (1993). "Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo". European Psychiatry. 8 (4): 201–208. doi:10.1017/S0924933800002923. ISSN 0924-9338. S2CID 151797528. Archived from the original on July 7, 2023. Retrieved February 21, 2021.
- O'Brien CP, Dackis CA, Kampman K (June 2006). "Does modafinil produce euphoria?". The American Journal of Psychiatry. 163 (6): 1109. doi:10.1176/ajp.2006.163.6.1109. PMID 16741217.
- Ballon JS, Feifel D (April 2006). "A systematic review of modafinil: Potential clinical uses and mechanisms of action" (PDF). The Journal of Clinical Psychiatry. 67 (4): 554–566. doi:10.4088/jcp.v67n0406. PMID 16669720. S2CID 17047074. Archived from the original (PDF) on February 20, 2019.
- International Narcotics Control Board (July 2020), Yellow List: List of Narcotic Drugs Under International Control, In accordance with the Single Convention on Narcotic Drugs, 1961 [Protocol of March 25, 1972, amending the Single Convention on Narcotic Drugs, 1961] (59th ed.), Yellow List PDF, archived from the original on January 16, 2022, retrieved January 12, 2022
- International Narcotics Control Board (July 2020), Green List: List of Psychotropic Substances Under International Control, In accordance with Convention psychotropic substances of 1971 (31st ed.), United Nations Publications, archived from the original on January 18, 2022, retrieved January 12, 2022
- Sangroula D, Motiwala F, Wagle B, Shah VC, Hagi K, Lippmann S (August 2017). "Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-Analysis". Substance Use & Misuse. 52 (10): 1292–1306. doi:10.1080/10826084.2016.1276597. PMID 28350194. S2CID 4775658.
- "Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers". FDA. May 26, 2021. Archived from the original on November 4, 2020. Retrieved April 8, 2022.
- "Cytochrome P450 3A (including 3A4) inhibitors and inducers". UpToDate. Archived from the original on April 8, 2022. Retrieved April 8, 2022.
- Philmore R (March 8, 2013). "Effect of Modafinil at Steady State on the Single-Dose Pharmacokinetic Profile of Warfarin in Healthy Volunteers". The Journal of Clinical Pharmacology. 42 (12): 205–214. doi:10.1177/00912700222011120. PMID 11831544. S2CID 29223738. Archived from the original on October 28, 2022. Retrieved October 28, 2022.
- Zhu HJ, Wang JS, Donovan JL, Jiang Y, Gibson BB, DeVane CL, Markowitz JS (January 2008). "Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein". European Journal of Pharmacology. 578 (2–3): 148–158. doi:10.1016/j.ejphar.2007.09.035. PMC 2659508. PMID 17963743.
- "Modafinil drug interactions". Drugs.com. Archived from the original on May 3, 2021. Retrieved May 3, 2021.
- "National Institutes Drug Information: Modafinil". NIH. July 1, 2005. Archived from the original on June 10, 2007. Retrieved July 21, 2007.
- Minzenberg MJ, Carter CS (June 2008). "Modafinil: a review of neurochemical actions and effects on cognition". Neuropsychopharmacology. Springer Science and Business Media LLC. 33 (7): 1477–1502. doi:10.1038/sj.npp.1301534. PMID 17712350. S2CID 13752498.
- Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM (November 2006). "Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers". Journal of Psychopharmacology. SAGE Publications. 20 (6): 756–770. doi:10.1177/0269881106060770. PMID 16401653. S2CID 8033437.
- Niwa T, Murayama N, Imagawa Y, Yamazaki H (May 2015). "Regioselective hydroxylation of steroid hormones by human cytochromes P450". Drug Metabolism Reviews. Informa UK Limited. 47 (2): 89–110. doi:10.3109/03602532.2015.1011658. PMID 25678418. S2CID 5791536.
- Aquinos BM, García Arabehety J, Canteros TM, de Miguel V, Scibona P, Fainstein-Day P (2021). "[Adrenal crisis associated with modafinil use]". Medicina (in Spanish). 81 (5): 846–849. PMID 34633961.
- Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, et al. (May 2009). "Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil". The Journal of Pharmacology and Experimental Therapeutics. 329 (2): 738–746. doi:10.1124/jpet.108.146142. PMC 2672878. PMID 19197004.
- Krief S, Berrebi-Bertrand I, Nagmar I, Giret M, Belliard S, Perrin D, et al. (October 2021). "Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol". Pharmacology Research & Perspectives. 9 (5): e00855. doi:10.1002/prp2.855. PMC 8381683. PMID 34423920.
- Murillo-Rodríguez E, Barciela Veras A, Barbosa Rocha N, Budde H, Machado S (February 2018). "An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil". ACS Chemical Neuroscience. 9 (2): 151–158. doi:10.1021/acschemneuro.7b00374. PMID 29115823.
- Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, et al. (September 2012). "R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse". Biological Psychiatry. 72 (5): 405–413. doi:10.1016/j.biopsych.2012.03.022. PMC 3413742. PMID 22537794.
- Seeman P, Guan HC, Hirbec H (August 2009). "Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil". Synapse. 63 (8): 698–704. doi:10.1002/syn.20647. PMID 19391150. S2CID 17758902.
- Thorpy MJ, Bogan RK (April 2020). "Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications". Sleep Med. 68: 97–109. doi:10.1016/j.sleep.2019.09.001. PMID 32032921. S2CID 203405397.
- Stahl SM (March 2017). "Modafinil". Prescriber's Guide: Stahl's Essential Psychopharmacology (6th ed.). Cambridge, United Kingdom: Cambridge University Press. pp. 491–495. ISBN 9781108228749.
- Gerrard P, Malcolm R (June 2007). "Mechanisms of modafinil: A review of current research". Neuropsychiatric Disease and Treatment. 3 (3): 349–364. PMC 2654794. PMID 19300566.
- Ishizuka T, Murotani T, Yamatodani A (2012). "Action of modafinil through histaminergic and orexinergic neurons". Sleep Hormones. Vitamins & Hormones. Vol. 89. pp. 259–78. doi:10.1016/B978-0-12-394623-2.00014-7. ISBN 9780123946232. PMID 22640618.
- Salerno M, Villano I, Nicolosi D, Longhitano L, Loreto C, Lovino A, et al. (January 2019). "Modafinil and orexin system: interactions and medico-legal considerations". Frontiers in Bioscience. 24 (3): 564–575. doi:10.2741/4736. PMID 30468674. S2CID 53713777.
- Ishizuka T, Murakami M, Yamatodani A (January 2008). "Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats". European Journal of Pharmacology. 578 (2–3): 209–215. doi:10.1016/j.ejphar.2007.09.009. PMID 17920581.
- Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK (July 2007). "Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants". European Journal of Pharmacology. 568 (1–3): 112–123. doi:10.1016/j.ejphar.2007.03.044. PMID 17477916.
- Murillo-Rodríguez E, Haro R, Palomero-Rivero M, Millán-Aldaco D, Drucker-Colín R (January 2007). "Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats". Behavioural Brain Research. 176 (2): 353–357. doi:10.1016/j.bbr.2006.10.016. PMID 17098298. S2CID 30192761.
- de Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S (November 2001). "Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats". NeuroReport. 12 (16): 3533–3537. doi:10.1097/00001756-200111160-00032. PMID 11733706. S2CID 31726815.
- Gallopin T, Luppi PH, Rambert FA, Frydman A, Fort P (February 2004). "Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study". Sleep. 27 (1): 19–25. PMID 14998233.
- Ferraro L, Fuxe K, Tanganelli S, Tomasini MC, Rambert FA, Antonelli T (April 2002). "Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression". Journal of Neuroscience Research. 68 (1): 107–112. doi:10.1002/jnr.10196. PMID 11933055. S2CID 43731660.
- Federici M, Latagliata EC, Rizzo FR, Ledonne A, Gu HH, Romigi A, et al. (November 2013). "Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation". Neuroscience. 252: 118–124. doi:10.1016/j.neuroscience.2013.07.071. PMID 23933217. S2CID 7588529.
- Okunola-Bakare OM, Cao J, Kopajtic T, Katz JL, Loland CJ, Shi L, Newman AH (February 2014). "Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues". Journal of Medicinal Chemistry. 57 (3): 1000–1013. doi:10.1021/jm401754x. PMC 3954497. PMID 24494745.
- Young JW (March 2009). "Dopamine D1 and D2 receptor family contributions to modafinil-induced wakefulness". The Journal of Neuroscience. 29 (9): 2663–2665. doi:10.1523/JNEUROSCI.5843-08.2009. PMC 2697968. PMID 19261860.
- Wisor J (October 2013). "Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions". Frontiers in Neurology. 4: 139. doi:10.3389/fneur.2013.00139. PMC 3791559. PMID 24109471.
- Kim W, Tateno A, Arakawa R, Sakayori T, Ikeda Y, Suzuki H, Okubo Y (May 2014). "In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [¹⁸F]FE-PE2I". The International Journal of Neuropsychopharmacology. 17 (5): 697–703. doi:10.1017/S1461145713001612. PMID 24451483.
- Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. (March 2009). "Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications". JAMA. 301 (11): 1148–1154. doi:10.1001/jama.2009.351. PMC 2696807. PMID 19293415.
- Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, et al. (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence. 147: 1–19. doi:10.1016/j.drugalcdep.2014.12.005. PMC 4297708. PMID 25548026.
- Quisenberry AJ, Baker LE (December 2015). "Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats". Psychopharmacology. 232 (24): 4411–4419. doi:10.1007/s00213-015-4065-0. PMID 26374456. S2CID 15519396.
- Mereu M, Bonci A, Newman AH, Tanda G (October 2013). "The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders". Psychopharmacology. 229 (3): 415–434. doi:10.1007/s00213-013-3232-4. PMC 3800148. PMID 23934211.
- Tanda G, Hersey M, Hempel B, Xi ZX, Newman AH (February 2021). "Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder". Current Opinion in Pharmacology. 56: 13–21. doi:10.1016/j.coph.2020.07.007. PMC 8247144. PMID 32927246.
- Stickgold R, Walker WP (May 22, 2010). The Neuroscience of Sleep. Academic Press. pp. 191–. ISBN 978-0-12-375722-7.
- Simon P, Hémet C, Ramassamy C, Costentin J (December 1995). "Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice". European Neuropsychopharmacology. 5 (4): 509–514. doi:10.1016/0924-977x(95)00041-m. PMID 8998404.
- Dunn D, Hostetler G, Iqbal M, Marcy VR, Lin YG, Jones B, et al. (June 2012). "Wake promoting agents: search for next generation modafinil, lessons learned: part III". Bioorganic & Medicinal Chemistry Letters. 22 (11): 3751–3753. doi:10.1016/j.bmcl.2012.04.031. PMID 22546675.
- Chatterjie N, Stables JP, Wang H, Alexander GJ (August 2004). "Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity". Neurochemical Research. 29 (8): 1481–1486. doi:10.1023/b:nere.0000029559.20581.1a. PMID 15260124. S2CID 956077.
- Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, Carrà G (November 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID 34509090. S2CID 237485915.
- Korotkova TM, Klyuch BP, Ponomarenko AA, Lin JS, Haas HL, Sergeeva OA (February 2007). "Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors". Neuropharmacology. 52 (2): 626–633. doi:10.1016/j.neuropharm.2006.09.005. PMID 17070873. S2CID 33713638.
- Rasetti R, Mattay VS, Stankevich B, Skjei K, Blasi G, Sambataro F, et al. (September 2010). "Modulatory effects of modafinil on neural circuits regulating emotion and cognition". Neuropsychopharmacology. 35 (10): 2101–2109. doi:10.1038/npp.2010.83. PMC 3013347. PMID 20555311.
- van Vliet SA, Jongsma MJ, Vanwersch RA, Olivier B, Philippens IH (May 2006). "Behavioral effects of modafinil in marmoset monkeys". Psychopharmacology. 185 (4): 433–440. doi:10.1007/s00213-006-0340-4. hdl:1874/19740. PMID 16550386. S2CID 12681062.
- ePainAssist Team (March 20, 2018). "What Happens If Amygdala Is Damaged?". Epainassist. Archived from the original on September 6, 2022. Retrieved August 24, 2022.
- "APA PsycNet". psycnet.apa.org. Archived from the original on July 7, 2023. Retrieved January 9, 2023.
- Mohamed AD (March 2, 2017). "Does modafinil improve cognitive functioning in healthy individuals?". In ter Meulen R, Mohammed A, Hall W (eds.). Rethinking Cognitive Enhancement. Oxford University Press. pp. 107–124. doi:10.1093/acprof:oso/9780198727392.003.0007. ISBN 978-0-19-872739-2. Retrieved November 15, 2023.
- Gilman A, Goodman LS, Hardman JG, Limbird LE (2001). Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill. p. 1984. ISBN 978-0-07-135469-1.
- Schwertner HA, Kong SB (March 2005). "Determination of modafinil in plasma and urine by reversed phase high-performance liquid-chromatography". Journal of Pharmaceutical and Biomedical Analysis. 37 (3): 475–479. doi:10.1016/j.jpba.2004.11.014. PMID 15740906. Archived from the original on August 4, 2020. Retrieved July 4, 2019.
- Wong YN, Wang L, Hartman L, Simcoe D, Chen Y, Laughton W, et al. (October 1998). "Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers". Journal of Clinical Pharmacology. 38 (10): 971–978. doi:10.1002/j.1552-4604.1998.tb04395.x. PMID 9807980. S2CID 32857213.
- Robertson P, Hellriegel ET, Arora S, Nelson M (January 2002). "Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers". Clinical Pharmacology and Therapeutics. 71 (1): 46–56. doi:10.1067/mcp.2002.121217. PMID 11823757. S2CID 21552865.
- Vetrivelan R, Saper CB, Fuller PM (2014). "Armodafinil-induced wakefulness in animals with ventrolateral preoptic lesions". Nature and Science of Sleep. 6: 57–63. doi:10.2147/NSS.S53132. PMC 4014362. PMID 24833927.
- Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE (March 1998). "Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers". Journal of Clinical Pharmacology. 38 (3): 276–282. doi:10.1002/j.1552-4604.1998.tb04425.x. PMID 9549666. S2CID 26877375.
- Baselt RC (2008). Disposition of Toxic Drugs and Chemicals in Man. Foster City, CA: Biomedical Publications. pp. 1152–1153. ISBN 978-0-9626523-7-0.
- Spratley TK, Hayes PA, Geer LC, Cooper SD, McKibben TD (2005). "Analytical Profiles for Five "Designer" Tryptamines" (PDF). Microgram Journal. 3 (1–2): 54–68. Archived (PDF) from the original on August 2, 2020. Retrieved December 18, 2015.
- "Modafinil reaction with the Froehde reagent and others". Reagent Tests UK. December 13, 2015. Archived from the original on August 3, 2020. Retrieved December 18, 2015.
- De Risi C, Ferraro L, Pollini GP, Tanganelli S, Valente F, Veronese AC (December 2008). "Efficient synthesis and biological evaluation of two modafinil analogues". Bioorganic & Medicinal Chemistry. 16 (23): 9904–9910. doi:10.1016/j.bmc.2008.10.027. PMID 18954992.
- Napoletano F, Schifano F, Corkery JM, Guirguis A, Arillotta D, Zangani C, Vento A (2020). "The Psychonauts' World of Cognitive Enhancers". Frontiers in Psychiatry. 11: 546796. doi:10.3389/fpsyt.2020.546796. PMC 7516264. PMID 33024436.
- Ballas CA, Kim D, Baldassano CF, Hoeh N (July 2002). "Modafinil: past, present and future". Expert Review of Neurotherapeutics. 2 (4): 449–457. doi:10.1586/14737126.96.36.1999. PMID 19810941. S2CID 32939239.
- Healy M (May 2, 2013). "Use of wake-up drug modafinil takes off, spurred by untested uses". Los Angeles Times. Archived from the original on December 18, 2013. Retrieved December 31, 2013.
- Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J (February 21, 2012). Alessi-Severini S (ed.). "The prevalence and cost of unapproved uses of top-selling orphan drugs". PLOS ONE. 7 (2): e31894. Bibcode:2012PLoSO...731894K. doi:10.1371/journal.pone.0031894. PMC 3283698. PMID 22363762.
- "Cephalon: Modafinil - Pharmaceutical industry news".
- Gellad WF, Choi P, Mizah M, Good CB, Kesselheim AS (March 2014). "Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011". Am J Manag Care. 20 (3): e90–7. PMID 24773330.
- "Generic Provigil Availability".
- US 4927855
- "Cephalon gets six-month Provigil patent extension". Philadelphia Business Journal. March 28, 2006. Archived from the original on August 4, 2008. Retrieved July 21, 2007.
- "Details for Patent: RE37516". Archived from the original on January 1, 2014. Retrieved November 29, 2009.
- "Prescription Access Litigation (PAL) Project :: Prescription Access Litigation (PAL) Project :: Lawsuits & Settlements :: Current Lawsuits". Prescriptionaccess.org. Archived from the original on June 19, 2012.
- "EU fines Teva and Cephalon €60.5m for 'pay for delay' scheme". pharmaphorum. Retrieved November 15, 2023.
- "Document 514 :: APOTEX, INC. v. CEPHALON, INC. et al". Pennsylvania Eastern District Court :: US Federal District Courts Cases :: Justia. October 31, 2010. Archived from the original on January 1, 2014. Retrieved July 4, 2012.
- "Document 513 :: APOTEX, INC. v. CEPHALON, INC. et al". Pennsylvania Eastern District Court :: US Federal District Courts Cases :: Justia. October 31, 2010. Archived from the original on January 1, 2014. Retrieved July 4, 2012.
- "Cephalon Inc., SEC 10K 2008 disclosure". February 23, 2009. pp. 9–10. Archived from the original on August 27, 2017. Retrieved August 29, 2009.
- "CVS, Rite Aid Sue Cephalon Over Generic Provigil". Bloomberg News. August 21, 2009. Retrieved August 29, 2009.
- IN RE: MODAFINIL ANTITRUST LITIGATION (Court of Appeals, 3rd Circuit 2016).
- "Canada IP Year in Review 2008". January 1, 2009. Archived from the original on January 5, 2020. Retrieved August 29, 2009.
- "Shire v. Canada". Archived from the original on April 24, 2010.
- "Cephalon Sues Apotex". Zacks.com. August 20, 2010. Archived from the original on March 5, 2012. Retrieved July 4, 2012.
- ""U.S. Federal Trade Commission Clears Teva's Acquisition of Cephalon". Business Wire. October 7, 2011. Archived from the original on April 18, 2016.
Teva will also grant non-exclusive U.S. rights to an undisclosed company to market modafinil tablets, the generic version of Provigil(R), which had annual brand sales in the U.S. of approximately $1.1 billion
- "Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals". Press Release. PRNewswire. October 18, 2011. Archived from the original on April 16, 2012. Retrieved July 4, 2012.
- Larson E (November 19, 2010). "Cephalon Loses U.K. Bid to Halt Mylan, Orchid Generic-Drug Sales". bloomberg LP. Archived from the original on November 25, 2010. Retrieved January 28, 2019.
- "Poisons Standard March 2018". Legislation.gov.au. Archived from the original on August 7, 2020. Retrieved January 20, 2019.
- "Regulations Amending the Food and Drug Regulations (1184 — Modafinil)". Canada Gazette. 140 (20). March 26, 2005. Archived from the original on July 6, 2011.
- "食品药品监管总局 公安部 国家卫生计生委关于公布麻醉药品和精神药品品种目录的通知". China Food and Drug Administration. Archived from the original on December 5, 2018.
- "处方管理办法（原卫生部令第53号）". 中国政府网 (in Chinese). Archived from the original on February 8, 2020. Retrieved February 8, 2019.
- "HOTĂRÂRE Nr. 79 din 23-01-2006 privind aprobarea Listei substanţelor stupefiante, psihotrope şi a plantelor care conţin astfel de substanţe depistate în trafic ilicit, precum şi cantităţile acestora".
- "Serviciul Vamal al Republicii Moldova - E bine să știm!". customs.gov.md.
- "Data" (PDF). base.consultant.ru. Archived from the original on August 28, 2021. Retrieved January 3, 2017.
- "List of psychotropics" (PDF). Archived from the original (PDF) on July 11, 2019. Retrieved May 24, 2019.
- "モダフィニルの向精神薬への指定". Archived from the original on May 15, 2015. Retrieved January 17, 2017.
- "医疗用医薬品の添付文书情报-モディオダール锭１００ｍｇ". 独立行政法人 医薬品医疗机器総合机构 (in Japanese). Archived from the original on February 9, 2019.
- "モダフィニル密輸で逮捕された歯科医師，ダイエットに使用と供述（報道）". Medicallaw.exblog.jp. Archived from the original on January 21, 2019. Retrieved January 20, 2019.
- "向精神薬をインドから密輸入した男を逮捕". Hayabusa3.5ch.net. Archived from the original on January 21, 2019. Retrieved January 20, 2019.
- "AGENȚIA NAȚIONALĂ ANTI-DOPING" (PDF). Archived from the original (PDF) on February 24, 2021.
- "LEGE 219 26/07/2021 - Portal Legislativ". Archived from the original on October 16, 2022. Retrieved October 16, 2022.
- "Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika" (PDF). Archived from the original (PDF) on August 7, 2019.
- "Is It Illegal to Obtain Controlled Substances From the Internet?". United States Drug Enforcement Administration. Archived from the original on July 9, 2007. Retrieved July 21, 2007.
- U.S. Justice Department (January 27, 1999). "Schedules of Controlled Substances: Placement of Modafinil Into Schedule IV". Federal Register: The Daily Journal of the United States Government. 64 FR 4050. Archived from the original on July 28, 2021. Retrieved January 12, 2022.
A Rule by the Justice Department on 01/27/1999
- "USC 201 Section 1301.26 Exemptions from import or export requirements for personal medical use". United States Department of Justice. March 24, 1997. Archived from the original on February 3, 2007. Retrieved January 10, 2007.
- "Prescription Drug Marketing Act of 1987 (PDMA), PL 100-293". U.S. Food and Drug Administration. Archived from the original on February 23, 2008.
- "Letter to Cephalon 01/03/2002". Food and Drug Administration. January 3, 2002. Archived from the original on April 8, 2013. Retrieved July 4, 2012.
- Allison J (October 9, 2009). "Class Action Over Cephalon Off-Label Claims Tossed". www.law360.com. Law360. Archived from the original on April 30, 2022. Retrieved January 12, 2022.
Cephalon executives have repeatedly said that they do not condone off-label use of Provigil, but in 2002 the company was reprimanded by the FDA for distributing marketing materials that presented the drug as a remedy for tiredness, "decreased activity" and other supposed ailments. In 2008, Cephalon paid $425m and pleaded guilty to a federal criminal charge relating to its promotion of off-label uses for Provigil and two other drugs.
- Zieger A (September 30, 2008). "Cephalon settlement requires physician payments to be disclosed". Fierce Healthcare. Archived from the original on May 24, 2013. Retrieved June 7, 2012.
- "Lääkealan turvallisuus- ja kehittämiskeskuksen päätöslääkeluettelosta". Finlex.fi. 2009. Archived from the original on August 23, 2020. Retrieved January 3, 2017.
- "Bekendtgørelse om euforiserende stoffer" [Narcotics act]. Retsinformation.dk (in Danish). June 23, 2020. Archived from the original on November 28, 2020. Retrieved October 7, 2020.
- "Estupefacientes y Psicotrópicos" [Narcotic Drugs and Psychotropic Substances] (in Spanish). Federal Commission for Protection against Health Risks. Archived from the original on July 13, 2007.
- SA Government (April 10, 2003). "GENERAL REGULATIONS MADE IN TERMS OF THE MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965, AS AMENDED Government Notice R510 in Government Gazette 24727 dated 10 April 2003. 22A/16/b; states that although import and export is restricted, possession is not illegal providing that a prescription is present" (PDF). Pretoria: SAFLII. Archived from the original (PDF) on April 22, 2016.
- MHRA (April 3, 2013). "MHRA license for Modafinil in UK" (PDF). London: MHRA. Archived (PDF) from the original on January 22, 2016. Retrieved April 3, 2013.
- "Modafinil – International Brands". Drugs.com. Archived from the original on July 18, 2020. Retrieved January 8, 2017.
- ""Pay-For-Delay": The EC fines Teva and Cephalon for delaying the market entry of a generic version of Modafinil".
- "Modafinil Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved November 16, 2023.
- Syyed S (November 1, 2023). "Where to Buy Modafinil in Canada in 2023". Modafinil.org. Retrieved November 16, 2023.
- World Anti-Doping Agency (September 5, 2017). "Prohibited List 2018" (PDF). The World Anti-Doping Code: International Standard. Archived from the original on July 3, 2021. Retrieved January 12, 2022.
- "Clinger given lifetime ban for second doping infraction". Cycling News. August 14, 2011. Archived from the original on October 13, 2014. Retrieved October 8, 2014.
- "Taurasi tested positive for modafinil". The Washington Post. December 25, 2010. Archived from the original on October 6, 2014. Retrieved December 31, 2013.
- Guardian Sport (November 23, 2015). "British rowers handed two-year bans for taking banned substances". The Guardian. Archived from the original on July 9, 2020. Retrieved December 15, 2016.
- Voepel M (February 18, 2011). "Taurasi: 'I've lost 3 months of my career'". Archived from the original on October 6, 2015. Retrieved April 11, 2011.
- "White guilty of doping". September 9, 2003 – via news.bbc.co.uk.
- "Bonds Exposed". Sports Illustrated. March 7, 2006.
- Jacobs I, Bell DG (June 2004). "Effects of acute modafinil ingestion on exercise time to exhaustion". Medicine and Science in Sports and Exercise. 36 (6): 1078–1082. doi:10.1249/01.MSS.0000128146.12004.4F. PMID 15179180. S2CID 25400053.
- Is Provigil the secret to success?. Retrieved November 15, 2023.
- "The rise of smart drugs". March 16, 2016.
- "We asked Sussex University if Modafinil is cheating". November 6, 2017.
- Porsdam Mann S, de Lora Deltoro P, Cochrane T, Mitchell C (2018). "Is the use of modafinil, a pharmacological cognitive enhancer, cheating?". Ethics and Education. 13 (2): 251–267. doi:10.1080/17449642.2018.1443050. S2CID 149138516.
- "PPT - Should taking Modafinil be Considered as Cheating PowerPoint Presentation - ID:7522407". March 6, 2017.
- Teodorini RD, Rycroft N, Smith-Spark JH (2020). "The off-prescription use of modafinil: An online survey of perceived risks and benefits". PLOS ONE. 15 (2): e0227818. Bibcode:2020PLoSO..1527818T. doi:10.1371/journal.pone.0227818. PMC 7001904. PMID 32023288.
- Kornum BR, Knudsen S, Ollila HM, Pizza F, Jennum PJ, Dauvilliers Y, Overeem S (February 2017). "Narcolepsy". Nat Rev Dis Primers. 3: 16100. doi:10.1038/nrdp.2016.100. PMID 28179647.
- Modafinil - Music to Mod to. YouTube.
- Matthew Dear - Modafinil Blues. Retrieved November 15, 2023.
- Joe Rogan Talks About Modafinil [Provigil] – via www.youtube.com.
- Joe Rogan talks about his own experience with Modafinil – via www.youtube.com.
- Modafinil Experience: Joe Rogan, Tim Ferriss, and Dave Asprey Talk About Smart Drug – via www.youtube.com.
- Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S (May 2017). "Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence". European Neuropsychopharmacology. 27 (5): 423–441. doi:10.1016/j.euroneuro.2017.03.003. PMID 28318897. S2CID 3740987.
- McIntyre RS, Lee Y, Zhou AJ, Rosenblat JD, Peters EM, Lam RW, et al. (August 2017). "The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis". Journal of Clinical Psychopharmacology. 37 (4): 412–418. doi:10.1097/JCP.0000000000000723. PMID 28590365. S2CID 27622964.
- Bahji A, Mesbah-Oskui L (September 2021). "Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis". Journal of Affective Disorders. 292: 416–423. doi:10.1016/j.jad.2021.05.119. PMID 34144366.
- Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH (November 2013). "Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials". The Journal of Clinical Psychiatry. 74 (11): 1101–1107. doi:10.4088/JCP.13r08560. PMID 24330897.
- Corp SA, Gitlin MJ, Altshuler LL (September 2014). "A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder". The Journal of Clinical Psychiatry. 75 (9): 1010–1018. doi:10.4088/JCP.13r08851. PMID 25295426.
- Malhi GS, Byrow Y, Bassett D, Boyce P, Hopwood M, Lyndon W, et al. (March 2016). "Stimulants for depression: On the up and up?". The Australian and New Zealand Journal of Psychiatry. 50 (3): 203–207. doi:10.1177/0004867416634208. PMID 26906078. S2CID 45341424.
- Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA (November 2010). "The neurobiology of the switch process in bipolar disorder: a review". J Clin Psychiatry. 71 (11): 1488–501. doi:10.4088/JCP.09r05259gre. PMC 3000635. PMID 20492846.
- Turner D (April 2006). "A review of the use of modafinil for attention-deficit hyperactivity disorder". Expert Review of Neurotherapeutics. 6 (4): 455–468. doi:10.1586/14737188.8.131.525. ISSN 1473-7175. PMID 16623645. S2CID 24293088.
- Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU (January 2017). "Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis". Journal of Psychiatric Research. 84: 292–300. doi:10.1016/j.jpsychires.2016.09.034. PMID 27810669.
- Buoli M, Serati M, Cahn W (2016). "Alternative pharmacological strategies for adult ADHD treatment: a systematic review". Expert Review of Neurotherapeutics. 16 (2): 131–144. doi:10.1586/14737175.2016.1135735. PMID 26693882. S2CID 33004517.
- Kooij JJ, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, et al. (February 2019). "Updated European Consensus Statement on diagnosis and treatment of adult ADHD". European Psychiatry. 56: 14–34. doi:10.1016/j.eurpsy.2018.11.001. PMID 30453134. S2CID 53714228.
- Ballon JS, Feifel D (April 2006). "A systematic review of modafinil: Potential clinical uses and mechanisms of action" (PDF). The Journal of Clinical Psychiatry. 67 (4): 554–566. doi:10.4088/jcp.v67n0406. PMID 16669720. S2CID 17047074. Archived from the original (PDF) on February 20, 2019. Retrieved November 14, 2020.
- Lindsay SE, Gudelsky GA, Heaton PC (October 2006). "Use of modafinil for the treatment of attention deficit/hyperactivity disorder". The Annals of Pharmacotherapy. 40 (10): 1829–1833. doi:10.1345/aph.1H024. PMID 16954326. S2CID 37368284.
- Hersey M, Bacon AK, Bailey LG, Coggiano MA, Newman AH, Leggio L, Tanda G (2021). "Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?". Frontiers in Neuroscience. 15: 656475. doi:10.3389/fnins.2021.656475. PMC 8187604. PMID 34121988.
- Schmitt KC, Reith ME (October 17, 2011). "The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors". PLOS ONE. 6 (10): e25790. Bibcode:2011PLoSO...625790S. doi:10.1371/journal.pone.0025790. PMC 3197159. PMID 22043293.
- O'Brien CP (September 2012). "Modafinil-cocaine interactions: clinical implications". Biological Psychiatry. 72 (5): 346. doi:10.1016/j.biopsych.2012.07.004. PMID 22872012. S2CID 39238847.
- Avelar AJ, Cao J, Newman AH, Beckstead MJ (September 2017). "Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons". Neuropharmacology. 123: 410–419. doi:10.1016/j.neuropharm.2017.06.016. PMC 5546153. PMID 28625719.
- Mereu M, Hiranita T, Jordan CJ, Chun LE, Lopez JP, Coggiano MA, et al. (August 2020). "Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions". Neuropsychopharmacology. 45 (9): 1518–1526. doi:10.1038/s41386-020-0680-5. PMC 7360549. PMID 32340023.
- Dürsteler KM, Berger EM, Strasser J, Caflisch C, Mutschler J, Herdener M, Vogel M (December 31, 2015). "Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence". Substance Abuse and Rehabilitation. 6: 61–74. doi:10.2147/SAR.S50807. PMC 4476488. PMID 26124696.
- >Wisor J (October 2013). "Modafinil as a catecholaminergic agent: Empirical evidence and unanswered questions". Frontiers in Neurology. 4: 139. doi:10.3389/fneur.2013.00139. ISSN 1664-2295. PMC 3791559. PMID 24109471.
- Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS (November 2010). "Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study". The Journal of Clinical Psychiatry. 71 (11): 1475–1481. doi:10.4088/jcp.09m05950gry. PMID 20816042.
- Andrade C, Kisely S, Monteiro I, Rao S (January 2015). "Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials" (PDF). Journal of Psychiatric Research. 60: 14–21. doi:10.1016/j.jpsychires.2014.09.013. PMID 25306261.
- Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S (July 2017). "Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence". JAMA Psychiatry. 74 (7): 675–684. doi:10.1001/jamapsychiatry.2017.0624. PMC 6584320. PMID 28514486.
- Kredlow MA, Keshishian A, Oppenheimer S, Otto MW (2019). "The Efficacy of Modafinil as a Cognitive Enhancer: A Systematic Review and Meta-Analysis". Journal of Clinical Psychopharmacology. 39 (5): 455–461. doi:10.1097/JCP.0000000000001085. PMID 31433334. S2CID 201119084.
- Roberts CA, Jones A, Sumnall H, Gage SH, Montgomery C (September 2020). "How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine" (PDF). European Neuropsychopharmacology. 38: 40–62. doi:10.1016/j.euroneuro.2020.07.002. PMID 32709551. S2CID 220651670. Archived (PDF) from the original on February 20, 2022. Retrieved February 2, 2022.
- Portela MA, Rubiales AS, Centeno C (June 2011). "The use of psychostimulants in cancer patients". Current Opinion in Supportive and Palliative Care. 5 (2): 164–168. doi:10.1097/SPC.0b013e3283462ff3. PMID 21532350. S2CID 39218702.
- Mücke M, Cuhls H, Peuckmann-Post V, Minton O, Stone P, Radbruch L (May 2015). "Pharmacological treatments for fatigue associated with palliative care". The Cochrane Database of Systematic Reviews. 30 (5): CD006788. doi:10.1002/14651858.CD006788.pub3. PMC 6483317. PMID 26026155.
- Kraft GH, Bowen J (December 2005). "Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study". Neurology. 65 (12): 1995–1997. doi:10.1212/01.wnl.0000200985.04239.53. PMID 16380634. S2CID 46704293.
- Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, et al. (January 2021). "Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial". The Lancet. Neurology. 20 (1): 38–48. doi:10.1016/S1474-4422(20)30354-9. PMC 7772747. PMID 33242419.
- Kim H, Ayele GM, Atalay RT, Hussien S, Tewoldemedhin B, Michael MB, Scharf SM (July 2022). "What Works for One May Not Work for Another: A New Warning for Modafinil". Cureus. 14 (7): e27287. doi:10.7759/cureus.27287. PMC 9413809. PMID 36043022.
- Vöckel J, Markser A, Wege L, Wunram HL, Sigrist C, Koenig J (October 2023). "Pharmacological anti-inflammatory treatment in children and adolescents with depressive symptoms: A systematic-review and meta-analysis". Eur Neuropsychopharmacol. 78: 16–29. doi:10.1016/j.euroneuro.2023.09.006. PMID 37864981. S2CID 264296074.
- Zager A (August 2020). "Modulating the immune response with the wake-promoting drug modafinil: A potential therapeutic approach for inflammatory disorders". Brain Behav Immun. 88: 878–886. doi:10.1016/j.bbi.2020.04.038. PMID 32311496. S2CID 215807973.
- Choi S, Kim JA, Li H, Jo SE, Lee H, Kim TH, Kim M, Kim SJ, Suh SH (December 2021). "Anti-inflammatory and anti-fibrotic effects of modafinil in nonalcoholic liver disease". Biomed Pharmacother. 144: 112372. doi:10.1016/j.biopha.2021.112372. PMID 34794237. S2CID 240194508.
- Dejban P, Eslami F, Rahimi N, Takzare N, Jahansouz M, Dehpour AR (November 2020). "Involvement of nitric oxide pathway in the anti-inflammatory effect of modafinil on indomethacin-, stress-, and ethanol -induced gastric mucosal injury in rat". Eur J Pharmacol. 887: 173579. doi:10.1016/j.ejphar.2020.173579. PMC 7495189. PMID 32950497.
- Omidi-Ardali H, Badi AG, Saghaei E, Amini-Khoei H (October 2020). "Nitric oxide mediates the antidepressant-like effect of modafinil in mouse forced swimming and tail suspension tests". J Basic Clin Physiol Pharmacol. 32 (2): 25–31. doi:10.1515/jbcpp-2020-0021. PMID 33011691. S2CID 222163522.
- Moradi F, Eslami F, Rahimi N, Koohfar A, Shayan M, Maadani M, Ghasemi M, Dehpour AR (May 2022). "Modafinil exerts anticonvulsive effects against lithium-pilocarpine-induced status epilepticus in rats: A role for tumor necrosis factor-α and nitric oxide signaling". Epilepsy Behav. 130: 108649. doi:10.1016/j.yebeh.2022.108649. PMID 35344809. S2CID 247683556.
- Aryannejad A, Gandominejad A, Tabary M, Noroozi N, Abbasi A, Araghi F, Mohammad Jafari R, Dehpour AR (June 2021). "Protective effect of modafinil on skin flap survival in the experimental random-pattern skin flap model in rats: The role of ATP-sensitive potassium channels and nitric oxide pathway". J Plast Reconstr Aesthet Surg. 74 (6): 1346–1354. doi:10.1016/j.bjps.2020.10.084. PMID 33279429. S2CID 227519680.
- Robbins RA, Grisham MB (June 1997). "Nitric oxide". Int J Biochem Cell Biol. 29 (6): 857–60. doi:10.1016/s1357-2725(96)00167-7. PMID 9304799.
- Guzik TJ, Korbut R, Adamek-Guzik T (December 2003). "Nitric oxide and superoxide in inflammation and immune regulation". J Physiol Pharmacol. 54 (4): 469–87. PMID 14726604.
- Ghasemi M (2019). "Nitric oxide: Antidepressant mechanisms and inflammation". Neuropsychotherapeutics. Adv Pharmacol. Vol. 86. pp. 121–152. doi:10.1016/bs.apha.2019.04.004. ISBN 9780128166680. PMID 31378250. S2CID 181642556.
- Han J, Chen D, Liu D, Zhu Y (April 2018). "Modafinil attenuates inflammation via inhibiting Akt/NF-κB pathway in apoE-deficient mouse model of atherosclerosis". Inflammopharmacology. 26 (2): 385–393. doi:10.1007/s10787-017-0387-3. PMID 28828622. S2CID 254580007.
- Crupi R, Cordaro M, Cuzzocrea S, Impellizzeri D (April 2020). "Management of Traumatic Brain Injury: From Present to Future". Antioxidants (Basel). 9 (4): 297. doi:10.3390/antiox9040297. PMC 7222188. PMID 32252390.
- Bagcioglu E, Solmaz V, Erbas O, Özkul B, Çakar B, Uyanikgil Y, Söğüt İ (June 2023). "Modafinil Improves Autism-like Behavior in Rats by Reducing Neuroinflammation". J Neuroimmune Pharmacol. 18 (1–2): 9–23. doi:10.1007/s11481-023-10061-2. PMID 37043086. S2CID 258080413.
- Li H, Kim JA, Jo SE, Lee H, Kim KC, Choi S, Suh SH (November 2023). "Modafinil exerts anti-inflammatory and anti-fibrotic effects by upregulating adenosine A2A and A2B receptors". Purinergic Signal. doi:10.1007/s11302-023-09973-8. PMID 37938538. S2CID 265050015.